Skip Navigation
Skip Website Tools

Dengue Fever

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Prevention Research

NIAID researchers are actively engaged in the search for an effective vaccine against dengue fever. The vaccine approach that is currently been evaluated at NIAID for efficacy against dengue animal models and human trials is a weakened recombinant version (live-attenuated) of the dengue virus. Other NIAID-funded investigators are working to develop dengue vaccines using different live-attenuated dengue viruses, recombinant proteins, viral vectors, and DNA.

Insecticide-treated bed nets have long been used to prevent malaria. One NIAID-funded study is evaluating the feasibility of using these nets as curtains in houses to prevent mosquitoes from entering homes. Studies on the behavior and geographical patterns of the mosquito vector can also inform prevention strategies. Research areas currently being supported by NIAID include the physiology of dengue vectors throughout the life cycle, the effects of urbanization on disease transmission, and how mosquitoes seek out mates and human hosts.

NIAID-supported researchers are also exploring alternate prevention methods, such as targeting dengue virus in the mosquito vector. By preventing dengue viruses from reproducing inside mosquitoes, researchers hope to reduce the transmission of diseases by mosquitoes.

Research Features

New Defense Mechanism against Dengue Identified in Mosquitoes

Modified Mosquitoes Could Save People from Dengue Fever

Infant Immunity May Show Path to Dengue Vaccine

NIAID Scientists Use Reverse Genetics to Develop Potential Dengue Vaccine 

Modified Mosquitoes Could Save People from Dengue Fever

Last Updated February 08, 2011